US Patent

US8557852 — Methods of using crystalline forms of a salt of a factor Xa inhibitor

Method of Use · Assigned to Millennium Pharmaceuticals Inc · Expires 2028-09-08 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for preventing or treating conditions with undesired thrombosis in mammals using a specific crystalline form of a maleate salt of a factor Xa inhibitor.

USPTO Abstract

The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa.

Drugs covered by this patent

Bevyxxa (BETRIXABAN) · Portola Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1167`	—	Bevyxxa
`U-1167`	—	Bevyxxa

Patent Metadata

Patent number: US8557852
Jurisdiction: US
Classification: Method of Use
Expires: 2028-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Millennium Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.